

Kazumasa Fujitani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9553108/publications.pdf>

Version: 2024-02-01

32
papers

1,422
citations

516215

16
h-index

414034

32
g-index

33
all docs

33
docs citations

33
times ranked

1973
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4438-4444.	0.8	439
2	Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. <i>British Journal of Surgery</i> , 2009, 96, 1015-1022.	0.1	198
3	Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 277-287.	3.7	141
4	Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. <i>Gastric Cancer</i> , 2014, 17, 206-212.	2.7	100
5	Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. <i>Gastric Cancer</i> , 2015, 18, 382-389.	2.7	53
6	Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East. <i>Digestive Surgery</i> , 2013, 30, 119-129.	0.6	49
7	Clinical Outcome and Indications for Palliative Gastrojejunostomy in Unresectable Advanced Gastric Cancer: Multi-Institutional Retrospective Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 3527-3533.	0.7	44
8	C-reactive protein on postoperative day 3 as a predictor of infectious complications following gastric cancer resection. <i>Gastric Cancer</i> , 2016, 19, 293-301.	2.7	43
9	Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. <i>European Journal of Cancer</i> , 2015, 51, 808-816.	1.3	40
10	Posttherapy Nodal Status, Not Graded Histologic Response, Predicts Survival after Neoadjuvant Chemotherapy for Advanced Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2012, 19, 1936-1943.	0.7	37
11	Significance of surgical treatment of liver metastases from gastric cancer. <i>Anticancer Research</i> , 2012, 32, 665-70.	0.5	35
12	Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?. <i>Gastric Cancer</i> , 2018, 21, 446-452.	2.7	33
13	Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. <i>Gastric Cancer</i> , 2014, 17, 348-353.	2.7	28
14	Effects of perioperative Eicosapentaenoic acid-enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. <i>Journal of Cancer</i> , 2019, 10, 1070-1076.	1.2	24
15	Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. <i>BJS Open</i> , 2017, 1, 165-174.	0.7	21
16	Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis. <i>Gastric Cancer</i> , 2012, 15, 245-251.	2.7	19
17	Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy. <i>JAMA Oncology</i> , 2020, 6, e193531.	3.4	16
18	Optimal treatment change criteria for advanced gastric cancer with non-measurable peritoneal metastasis: symptom/tumor marker-based versus CT-based. <i>Anticancer Research</i> , 2014, 34, 5169-74.	0.5	15

#	ARTICLE	IF	CITATIONS
19	Phase II Feasibility Study of Adjuvant S-1 plus Docetaxel for Stage III Gastric Cancer Patients after Curative D2 Gastrectomy. <i>Oncology</i> , 2011, 80, 296-300.	0.9	13
20	A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial. <i>Gastric Cancer</i> , 2018, 21, 811-818.	2.7	11
21	Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 224-231.	2.7	10
22	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial. <i>International Journal of Clinical Oncology</i> , 2020, 25, 301-311.	1.0	8
23	Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). <i>Gastric Cancer</i> , 2020, 23, 520-530.	2.7	8
24	Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and Mortality. <i>Annals of Surgical Oncology</i> , 2022, 29, 924-932.	0.7	7
25	Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. <i>Gastric Cancer</i> , 2021, 24, 197-204.	2.7	5
26	QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study. <i>Gastric Cancer</i> , 2021, 24, 1131-1139.	2.7	5
27	Survival analysis of a prospective multicenter observational study on surgical palliation among patients with malignant bowel obstruction caused by peritoneal dissemination of gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 422-429.	2.7	5
28	A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 867-874.	1.1	4
29	Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial. <i>Gastric Cancer</i> , 2021, 24, 467-476.	2.7	4
30	Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 160-167.	2.7	3
31	Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. <i>European Journal of Cancer</i> , 2020, 132, 159-167.	1.3	2
32	ASO Visual Abstract: A Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate and Operative Morbidity and Mortality. <i>Annals of Surgical Oncology</i> , 2021, , 1.	0.7	0